

Symeres and Axxam To Offer an Innovative Compound Library for High-Throughput Screens

Nijmegen (the Netherlands) and Bresso (Italy) - 9 December 2020

Symeres and **Axxam** have further consolidated their strategic relationship, providing integrated drug discovery and development services to clients around the world, by announcing the transfer of a library of approx. 80,000 lead-like compounds, Symegold, to Axxam for use in high-throughput screens.

The Symegold library was synthesised at Symeres, recently rebranded from MercachemSyncom, in the Netherlands, as part of the European Lead Factory (ELF) IMI-2 consortium, using state-of-the-art parallel synthesis and purification platforms available at the Nijmegen and Groningen sites. The design criteria for preparing this novel and unique compound collection were based on diverse lead-like properties and structural novelty, using proprietary, rigid, sp³-rich scaffolds synthesised in house via innovative chemistries.

The addition of the Symegold library from Symeres to Axxam's innovative 325,000 compound AXX^{DIV4.0} library provides Axxam and Symeres' clients with a world-class selection of screening sets, accessible singly or combined, for small-molecule drug discovery via high-throughput screening.

Dr. Eelco Ebbers, CEO of Symeres, commented, "We are very happy to offer this premium screening collection—the result of significant intellectual and technical effort by our parallel and medicinal chemistry teams in the Netherlands—via our strategic alliance with Axxam. This library of unique compounds will be an excellent starting point for hit-finding programs. Because of our knowledge of the chemistry of these library compounds, we are also able to follow up with fast hit optimization, providing additional benefits for our customers. The combination of high-quality chemistry, ADME-Tox, state-of-the-art assay development and high-throughput screening expertise is now accessible to our clients around the world."

Dr. Stefan Lohmer, CEO of Axxam, added, "We are continuously enlarging our screening compound collection, which we are considering as a kind of living and evolving organism, with high-quality entries. Therefore, we are very pleased that we can add the unique Symegold collection from our strategic partner, Symeres, resulting in a world-class screening collection composed of more than 400,000 compounds, available now for our customer screening projects."

About Symeres

Symeres is the leading mid-sized European contract research organization offering innovative synthetic and medicinal chemistry, early process research services, and GMP production to accelerate the drug discovery and development process in a flexible and cost-effective way. In addition, [Admescope](#), the wholly owned subsidiary of Symeres, offers a full platform of ADME-Tox, PK, metabolite ID, and MIST studies.

Symeres also offers integrated drug-discovery services from hit to clinic via a strategic alliance with Axxam. Working for many pharmaceutical and biotech companies throughout the world, Symeres is recognized for its high-quality products and services and its unprecedented problem-solving capabilities.

For more information, please visit: www.symeres.com

About Axxam

Axxam SpA is a privately owned iPRO (innovative Partner Research Organization) and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of discovery services for the entire life sciences industries, such as pharmaceutical, crop protection, animal health, cosmetics, and nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including assay development, compound management, HTS, hit identification, and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. For more information, please visit www.axxam.com.

For further information, please contact:

Dr. Russell Thomas

Head of Business Development

Symeres

Email: russell.thomas@symeres.com

Dr. Sabrina Corazza

Head of Business Development

Axxam

Email: sabrina.corazza.sc@axxam.com